

10530873

Rec' INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 03/11165

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K39/395 C07K16/28 C07K16/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| X | YE D ET AL: "AUGMENTATION OF A HUMANIZED ANTI-HER2 MAB 4D5 INDUCED GROWTH INHIBITION BY A HUMAN-MOUSE CHIMERIC ANTI-EGF RECEPTOR MAB C225" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 18, no. 3, 21 January 1999 (1999-01-21), pages 731-738, XP001096335 ISSN: 0950-9232 the whole document --- -/- | 1-32 |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

10 February 2004

Date of mailing of the international search report

18/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

| |
|---|
| International Application No PCT/EP 03/11165 |
|---|

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | SCHMIDT M ET AL: "A BIVALENT SINGLE-CHAIN ANTIBODY-TOXIN SPECIFIC FOR ERB-2 AND THE EGF RECEPTOR" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 65, no. 4, 8 February 1996 (1996-02-08), pages 538-546, XP000646380 ISSN: 0020-7136 page 538, right-hand column, line 17 - line 29 page 540; figure 1 page 541; figure 2 ---- | 1-32 |
| A | WO 02 055106 A (MERCK PATENT GMBH ; GOODMAN SIMON (DE); KREYSCH HANS-GEORG (DE)) 18 July 2002 (2002-07-18) the whole document ---- | 1-32 |
| A | WO 94 00136 A (MOLECULAR ONCOLOGY INC) 6 January 1994 (1994-01-06) the whole document ---- | 1-32 |
| A | KASPRZYK P G ET AL: "THERAPY OF AN ANIMAL MODEL OF HUMAN GASTRIC CANCER USING A COMBINATION OF ANTI-ERBB-2 MONOCLONAL ANTIBODIES" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 52, 15 May 1992 (1992-05-15), pages 2771-2776, XP001093195 ISSN: 0008-5472 the whole document ---- | 1-32 |
| A | BASELGA J ET AL: "PHASE II STUDY OF WEEKLY INTRAVENOUS RECOMBINANT HUMANIZED ANTI-P185HER2 MONOCLONAL ANTIBODY IN PATIENTS WITH HER2/NEU-OVEREXPRESSING METASTATIC BREAST CANCER" JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 14, no. 3, March 1996 (1996-03), pages 737-744, XP000918166 cited in the application the whole document ---- | 1-32 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 03/11165

| Patent document cited in search report | Publication date | | Patent family member(s) | | Publication date |
|--|------------------|--|---|--|--|
| WO 02055106 | A 18-07-2002 | CA CZ WO EP HU SK | 2436326 A1 20031927 A3 02055106 A2 1349574 A2 0302544 A2 9072003 A3 | | 18-07-2002 15-10-2003 18-07-2002 08-10-2003 28-10-2003 04-11-2003 |
| WO 9400136 | A 06-01-1994 | AU AU CA EP FI JP KR US WO | 687346 B2 3773393 A 2120745 A1 0655924 A1 941572 A 8504172 T 269879 B1 5587458 A 9400136 A1 | | 26-02-1998 24-01-1994 06-01-1994 07-06-1995 27-05-1994 07-05-1996 16-10-2000 24-12-1996 06-01-1994 |